TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9563140

Group type: COMPARATOR
Intervention: Chemical castration with leuprorelin acetate depot
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Complete androgen blockade (CAB) with leuprorelin plus flutamide
Number of subjects: 241
Study: 8110550

Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion (group A: 1.25 u. h‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Direct i.v. bolus administration of 10 u. every 2 h (group B: 10 u./2 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 60
Study: 3044040

Group type: COMPARATOR
Intervention: iopamidol (50 ml)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: iopamidol (100 ml)
Number of subjects: 126

Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 126

Group type: COMPARATOR
Intervention: diatrizoate (50 ml)
Number of subjects: 126
Study: 28142397

Group type: EXPERIMENTAL
Intervention: Stepwise multidisciplinary intervention (STA OP!)
Number of subjects: 288
Study: 27535128

Group type: EXPERIMENTAL
Intervention: Interactive mobile health management system for lay family health promoters and healthcare staff.
Number of subjects: 2000
Study: 23551502

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) applied to facial muscles associated with smiling.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no FES).
Number of subjects: 24
Study: 20674303

Group type: EXPERIMENTAL
Intervention: High antioxidant diet (HT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low antioxidant diet (LT)
Number of subjects: 24
Study: 20688800

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPT in combination with anti-depressant medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPT in combination with pill-placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-EMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard antidepressant therapy (medication, psychotherapy, or both)
Number of subjects: 0
Study: 18765878

Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) at a dosage of 20 mg/kg given deep intramuscular injections for 28 days (Group A)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sodium antimony gluconate (SAG) (Group B)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) for patients whose amastigotes were resistant or withdrew due to toxicity, treated with amphotericin B (AMB) at 1 mg/kg daily for 20 days
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Hospital stay duration
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Infectivity period
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Total expenditure on treatment
Number of subjects: 140
Study: 16216471

Group type: EXPERIMENTAL
Intervention: WHO Quality of Life Assessment Instrument (WHOQOL-100)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: WHOQOL-100
Number of subjects: 533
Study: 12854292

Group type: EXPERIMENTAL
Intervention: Comprehensive health promotion program for rheumatoid arthritis (CHPPRA)
Number of subjects: 36
Study: 10793505

Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Decompression Exercises (exercise program)
Number of subjects: 286
Study: 8853536

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (single-fraction radiation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (short-course fractionated treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (with 5HT3 antagonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-body irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 89-strontium
Number of subjects: 0
Study: 1894936

Group type: EXPERIMENTAL
Intervention: Acyclovir suppressively and for recurrences
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo suppressively and acyclovir for recurrences
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo suppressively and for recurrences
Number of subjects: 20
Study: 6653921

Group type: EXPERIMENTAL
Intervention: Domperidone, 10 mg intravenously
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31495558

Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 30344206

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 23
Study: 27965488

Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg TID for 21 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Betamethasone (4 mg/mL biweekly for 4 weeks)
Number of subjects: 20
Study: 24599462

Group type: EXPERIMENTAL
Intervention: Changing the input drive to neurons encoding a prioritized stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive cues indicating stimuli most probable for test
Number of subjects: 0
Study: 21756151

Group type: EXPERIMENTAL
Intervention: Q-switched alexandrite laser treatment with a 3-mm spot size
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Q-switched alexandrite laser treatment with a 4-mm spot size
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Q-switched alexandrite laser treatment with a 4-mm spot size (lower fluence)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Q-switched alexandrite laser treatment
Number of subjects: 36
Study: 20847757

Group type: EXPERIMENTAL
Intervention: DHA supplementation (20 mg/kg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 8
Study: 17288669

Group type: EXPERIMENTAL
Intervention: Stage-matched consciousness-raising writing exercise
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: BSE action-oriented exercise
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 55
Study: 15638901

Group type: EXPERIMENTAL
Intervention: Potassium-sensitivity test (PST) in patients with prostatitis
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pelvic pain and urgency/frequency (PUF) questionnaire in patients with prostatitis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pelvic pain and urgency/frequency (PUF) questionnaire in controls
Number of subjects: 64

Group type: COMPARATOR
Intervention: Potassium-sensitivity test (PST) in controls
Number of subjects: 64

Group type: COMPARATOR
Intervention: Urethral irrigation with KCl in controls
Number of subjects: 64

Group type: COMPARATOR
Intervention: Urethral irrigation with NaCl in controls
Number of subjects: 64

Group type: COMPARATOR
Intervention: Urethral irrigation with KCl and NaCl before injury in controls
Number of subjects: 64
Study: 12379573

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 161

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d
Number of subjects: 161
Study: 9846923

Group type: EXPERIMENTAL
Intervention: EMLA cream 5% (1 g applied for 60-70 min)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (1 g applied for 60-70 min)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: EMLA cream 5%
Number of subjects: 47
Study: 8124787

Group type: EXPERIMENTAL
Intervention: Sodium restriction treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 2801550

Group type: COMPARATOR
Intervention: Aspirin 325 mg daily (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Urokinase 3 x 10(6) U intravenously over 30 minutes followed by heparin
Number of subjects: 25
Study: 780378

Group type: EXPERIMENTAL
Intervention: 40 mg/day ripazepam (CI-683)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg/day ripazepam (CI-683)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31860856

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Transversus abdominis plane blockade (USG-TAP-blockade)
Number of subjects: 90
Study: 28601891

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 25894807

Group type: EXPERIMENTAL
Intervention: SIGN interlocking intramedullary nail
Number of subjects: 500
Study: 24113037

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 26
Study: 21834978

Group type: EXPERIMENTAL
Intervention: Intensive mannequin training (n = 40)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Brief mannequin training (Control group, n = 38)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Participants' self-assessment
Number of subjects: 126
Study: 19706565

Group type: EXPERIMENTAL
Intervention: Strong African American Families prevention program
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 641
Study: 17609906

Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI) plus Stanozolol (2 mg three times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stanozolol (2 mg three times a day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI) plus Stanozolol
Number of subjects: 60
Study: 15164436

Group type: EXPERIMENTAL
Intervention: Educational seminars for nurses on pain assessment and the use of a visual analogue scale (n = 3)
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Standard care (control group; n = 3)
Number of subjects: 2278
Study: 11405601

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 9086983

Group type: EXPERIMENTAL
Intervention: Rehabilitation-focused clinical pathway (group III)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consultation to rehabilitation services in the postoperative stay (group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Without a clinical pathway (group I)
Number of subjects: 0
Study: 8442963

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 180
Study: 3816532

Group type: EXPERIMENTAL
Intervention: Short‐Alcohol Dependence Data (SADD)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Alcohol Dependence Scale (ADS)
Number of subjects: 201
Study: 31154594

Group type: EXPERIMENTAL
Intervention: Level of work motivation at baseline
Number of subjects: 151
Study: 29318244

Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry (24 g d‐1, equivalent to 2 cups of fresh strawberries)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control powder
Number of subjects: 19
Study: 26571197

Group type: EXPERIMENTAL
Intervention: Home-visitation program
Number of subjects: 704

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 704
Study: 24973026

Group type: EXPERIMENTAL
Intervention: Usual care plus an 8-week intervention (brief CBT delivered by trained frontline mental health staff)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 66
Study: 22412067

Group type: EXPERIMENTAL
Intervention: Parenteral artesunate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral quinine
Number of subjects: 0
Study: 20810586

Group type: EXPERIMENTAL
Intervention: STIRR intervention
Number of subjects: 236

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control)
Number of subjects: 236
Study: 17992478

Group type: EXPERIMENTAL
Intervention: Psychosocial variables (gender, depressiveness)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Psychosocial variables (gender, age)
Number of subjects: 87
Study: 15848600

Group type: EXPERIMENTAL
Intervention: ACEI/ARB therapy (started within 14 months after surgery)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (never received ACEI/ARB)
Number of subjects: 52
Study: 14624284

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg bid p.o.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 22
Study: 10912979

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg (two doses)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 142
Study: 9037790

Group type: EXPERIMENTAL
Intervention: Baxter reanimation formula (ringer lactated saline, RLS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monafo hypertonic lactated saline (HLS)
Number of subjects: 40
Study: 1737254

Group type: EXPERIMENTAL
Intervention: Intravesical pressure device (1.5 kPa warning)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No device (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intravesical pressure device
Number of subjects: 102
Study: 6517812

Group type: EXPERIMENTAL
Intervention: iohexol 300 I/ml
Number of subjects: 50

Group type: COMPARATOR
Intervention: ioxaglate 320 mg I/ml
Number of subjects: 50
Study: 3533315

Group type: EXPERIMENTAL
Intervention: Regular moderate-intensity physical exercise (brisk walking to slow jogging)
Number of subjects: 0
Study: 31851011

Group type: EXPERIMENTAL
Intervention: Home exercise program (12-week duration, consisting of strengthening and stretching exercises)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 32
Study: 30025534

Group type: EXPERIMENTAL
Intervention: Full intervention (prescription review and league tables plus authorised feedback letter)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Partial intervention (prescription review and league tables)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (prescription review only)
Number of subjects: 51
Study: 28632394

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) diet
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Reduced Glycemic Load (RGL) diet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard Portion-Controlled (PC) diet
Number of subjects: 102
Study: 26198306

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Roux‐en‐Y gastric bypass (RYGB)
Number of subjects: 64
Study: 23880495

Group type: EXPERIMENTAL
Intervention: Resourceful Adolescent Parent Program (RAP‐P) plus Routine Care (RC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine Care (RC) only
Number of subjects: 48
Study: 21912242

Group type: EXPERIMENTAL
Intervention: Initial evaluation of ASA physical status grades
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Final evaluation of ASA physical status grades
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Agreement measurement
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Underestimation of physical status
Number of subjects: 1554
Study: 18190597

Group type: EXPERIMENTAL
Intervention: Western-style care sought by 858 (66.4%) of those with eye problems.
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Non-utilization of care associated with being illiterate (OR 3.7), rural dweller (OR 3.8), unemployed (OR 1.6), or farmer (OR 5.2).
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Lack of awareness of service availability (32.9%) was the most common reason for not seeking treatment.
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Attitudinal reasons (32.5%) were prevalent barriers to seeking care.
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Social (11.8%), economic (11.5%), and service-related (9.0%) issues were less prevalent barriers.
Number of subjects: 1470
Study: 16507195

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fibreoptic bronchoscope
Number of subjects: 56
Study: 14500062

Group type: EXPERIMENTAL
Intervention: Microwave ablation and atrial size reduction (n=24)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 43
Study: 10882447

Group type: EXPERIMENTAL
Intervention: Discoid lateral meniscus group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 68
Study: 8768943

Group type: EXPERIMENTAL
Intervention: Aponeuron
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1579327

Group type: EXPERIMENTAL
Intervention: hCG administration (2500 IU on days 3, 6, and 9 after ovulatory dose of 10,000 IU hCG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-treatment cycles (no luteal phase support)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: hCG administration
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-treatment cycles
Number of subjects: 67
Study: 3907322

Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day, administered 2 times a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31515555

Group type: EXPERIMENTAL
Intervention: First-line maintenance capecitabine + bevacizumab
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Capecitabine + oxaliplatin + bevacizumab or another reintroduction treatment
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Mutually adjusting models for BMI and SMI
Number of subjects: 533
Study: 30099829

Group type: EXPERIMENTAL
Intervention: 20 mg of cortisol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27687362

Group type: EXPERIMENTAL
Intervention: 90° bend created by an intubating stylet (90D group, 35 patients)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional insertion (C group, 35 patients)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 90° bend created by an intubating stylet (90D group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional insertion (C group)
Number of subjects: 70
Study: 24673497

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 22961517

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel(®)) applied to the donor-site chest wall
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel(®))
Number of subjects: 107
Study: 20525395

Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (individual and group sessions, reminiscence boxes, posters, exhibitions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminiscence intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no reminiscence intervention)
Number of subjects: 0
Study: 18332313

Group type: EXPERIMENTAL
Intervention: Voriconazole, 1%, eyedrops administered hourly for 4 doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Voriconazole, 1%, eyedrops administered every 6 hours for 3 days
Number of subjects: 10
Study: 15973769

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 201

Group type: COMPARATOR
Intervention: Chronic hepatitis B patients without lamivudine treatment
Number of subjects: 201
Study: 15071258

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 4052
Study: 10204975

Group type: EXPERIMENTAL
Intervention: High-protein meal (39% energy as protein for men, 32% energy as protein for women)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-protein meal (5% energy as protein for women)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 0
Study: 7722207

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal diet for postmenopausal women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term preventive measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHI clinical trial and observational study
Number of subjects: 0
Study: 1699989

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (100 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Terfenadine (120 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal Control (NC)
Number of subjects: 25
Study: 632980

Group type: EXPERIMENTAL
Intervention: Continuous iron supplementation
Number of subjects: 0
Study: 31605900

Group type: EXPERIMENTAL
Intervention: Superficial heating (SH)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Foam rolling (FR)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of SH + FR
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 29543077

Group type: EXPERIMENTAL
Intervention: 22 Fr unipolar resectoscope (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 26 Fr unipolar resectoscope (group B)
Number of subjects: 70
Study: 27324577

Group type: EXPERIMENTAL
Intervention: Contact-based antistigma presentation
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Education-based presentation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 198
Study: 24164645

Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene regimen including dental prophylaxis at baseline and oral hygiene instructions at baseline, 4 and 8 weeks.
Number of subjects: 120
Study: 22058209

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-thalidomide-dexamethasone
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Cyclophosphamide-vincristine-doxorubicin-dexamethasone
Number of subjects: 1111
Study: 19591604

Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health condition
Number of subjects: 60
Study: 17613946

Group type: EXPERIMENTAL
Intervention: Customized Employment Supports (CES) model
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard vocational counseling (control)
Number of subjects: 168
Study: 15377133

Group type: EXPERIMENTAL
Intervention: Terminalia arjuna (500 mg q8h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18